Literature DB >> 3540140

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

R D Moore, P S Lietman, C R Smith.   

Abstract

In an examination of the relationships among plasma aminoglycoside concentrations, the minimal inhibitory concentration (MIC) for the infecting organism, and therapeutic outcome, data were analyzed from 236 patients with gram-negative bacterial infections who were participants in four clinical trials of gentamicin, tobramycin, and amikacin. Clinical response to therapy occurred in 188 (80%) patients. Elevated maximal and mean peak aminoglycoside concentration/MIC ratios were strongly associated with clinical response (P less than .00001 and P less than .0001, respectively). A graded dose-response effect was found between an increasing maximal peak concentration/MIC ratio and clinical response. By logistic regression the peak concentration/MIC ratios were associated significantly with clinical response after adjustment for underlying severity of illness and other factors correlated with response. These results demonstrate that a high peak concentration relative to the MIC for the infecting organism is a major determinant of the clinical response to aminoglycoside therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3540140     DOI: 10.1093/infdis/155.1.93

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  275 in total

Review 1.  Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.

Authors:  R C Li; M Zhu; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 2.  New developments and concepts in antimicrobial therapy for intra-abdominal infections.

Authors:  Z Younes; D A Johnson
Journal:  Curr Gastroenterol Rep       Date:  2000-08

Review 3.  Aminoglycosides: activity and resistance.

Authors:  M P Mingeot-Leclercq; Y Glupczynski; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

Review 4.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

5.  BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia.

Authors:  Michael S Niederman; Jean Chastre; Kevin Corkery; James B Fink; Charles-Edouard Luyt; Miguel Sánchez García
Journal:  Intensive Care Med       Date:  2011-12-07       Impact factor: 17.440

6.  Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.

Authors:  Stefanie Hennig; Ross Norris; Carl M J Kirkpatrick
Journal:  Br J Clin Pharmacol       Date:  2007-11-08       Impact factor: 4.335

7.  Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin.

Authors:  P Van der Auwera
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

8.  Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.

Authors:  P Vic; S Ategbo; D Turck; M O Husson; V Launay; G A Loeuille; A Sardet; A Deschildre; D Druon; C Arrouet-Lagande
Journal:  Arch Dis Child       Date:  1998-06       Impact factor: 3.791

Review 9.  Once-daily aminoglycoside administration: new strategies for an old drug.

Authors:  J M Kovarik; I M Hoepelman; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-09       Impact factor: 3.267

10.  Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; B M Michel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.